What is Solid tumors Phase 1 C-met Kinase Inhibitor MSC2156119J Clinical Trial?

Category: Others

false

NCT01014936 is an open-label, dose-escalation, first-in-man (FIM) study designed to explore MSC2156119J, in subjects with advanced solid tumors who have not responded to previous therapies or for whom no other therapies are available.

No patients have reported taking Solid tumors Phase 1 C-met Kinase Inhibitor MSC2156119J Clinical Trial.
Last updated:
There are no evaluations for Solid tumors Phase 1 C-met Kinase Inhibitor MSC2156119J Clinical Trial.